Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Información selecta para pacientes y cuidadores que se encuentra disponible en Español.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

TRUMENBA®Highlights (Meningococcal Group B Vaccine)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use TRUMENBA safely and effectively. See full prescribing information for TRUMENBA.

TRUMENBA® (Meningococcal Group B Vaccine)
Suspension for intramuscular injection
Initial U.S. Approval: 2014

INDICATIONS AND USAGE

  • Trumenba is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age. (1)
  • The effectiveness of the two-dose schedule of Trumenba against diverse N. meningitidis serogroup B strains has not been confirmed. (1)

DOSAGE AND ADMINISTRATION

  • For intramuscular use only. (2)
  • Three-dose schedule: Administer a dose (0.5 mL) at 0, 1–2, and 6 months. (2.1)
  • Two-dose schedule: Administer a dose (0.5 mL) at 0 and 6 months. If the second dose is administered earlier than 6 months after the first dose, a third dose should be administered at least 4 months after the second dose. (2.1)

DOSAGE FORMS AND STRENGTHS

  • Suspension for intramuscular injection in 0.5 mL single-dose prefilled syringe. (3)

CONTRAINDICATIONS

  • Severe allergic reaction after a previous dose of Trumenba. (4)

WARNINGS AND PRECAUTIONS

Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting. (5.4)

ADVERSE REACTIONS

The most common solicited adverse reactions in adolescents and young adults were pain at the injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%). (6)


To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or VAERS at 1-800-822-7967 or http://vaers.hhs.gov.

USE IN SPECIFIC POPULATIONS

  • Pediatric Use: Safety and effectiveness have not been established in children <10 years of age. In a clinical study, 90% of infants <12 months of age who were vaccinated with a reduced dosage formulation had fever. (8.4)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 8/2019

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event